Abstract
Advances in pharmacotherapy for addiction continue, with an increasing number of medications available to treat addictions. However, existence of medications does not necessarily translate to access for people with addictions. The presentations in this symposium address access to addiction pharmacotherapy, as evidenced by management techniques used by private health plans, medication usage in the specialty treatment system, the role of buprenorphine in expanding opioid agonist treatment, and the development of a performance measure to track addiction pharmacotherapy usage.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
